Enliven Therapeutics (NASDAQ:ELVN) Stock Rating Reaffirmed by HC Wainwright

Enliven Therapeutics (NASDAQ:ELVN)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They presently have a $37.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 46.25% from the stock’s current price.

Several other equities analysts have also recently issued reports on the company. Robert W. Baird began coverage on Enliven Therapeutics in a report on Tuesday, June 11th. They issued an “outperform” rating and a $32.00 price objective for the company. Baird R W upgraded Enliven Therapeutics to a “strong-buy” rating in a research report on Tuesday, June 11th.

Enliven Therapeutics Trading Down 2.7 %

ELVN opened at $25.30 on Tuesday. Enliven Therapeutics has a 12-month low of $9.80 and a 12-month high of $27.67. The firm has a 50 day moving average of $23.19 and a two-hundred day moving average of $21.84. The firm has a market capitalization of $1.19 billion, a PE ratio of -13.11 and a beta of 1.09.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.17. As a group, analysts predict that Enliven Therapeutics will post -1.98 EPS for the current fiscal year.

Insider Activity

In related news, CFO Benjamin Hohl sold 4,250 shares of the company’s stock in a transaction dated Friday, September 27th. The stock was sold at an average price of $24.27, for a total value of $103,147.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 12,000 shares of the stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $22.49, for a total transaction of $269,880.00. Following the transaction, the insider now directly owns 1,077,936 shares of the company’s stock, valued at $24,242,780.64. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Benjamin Hohl sold 4,250 shares of the business’s stock in a transaction dated Friday, September 27th. The stock was sold at an average price of $24.27, for a total transaction of $103,147.50. The disclosure for this sale can be found here. Insiders have sold 125,805 shares of company stock worth $3,126,077 in the last ninety days. Company insiders own 29.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Quest Partners LLC raised its holdings in shares of Enliven Therapeutics by 87.3% during the second quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock valued at $37,000 after acquiring an additional 742 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Enliven Therapeutics by 67.0% during the first quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company’s stock worth $140,000 after purchasing an additional 3,189 shares in the last quarter. American Century Companies Inc. raised its stake in Enliven Therapeutics by 44.7% in the 2nd quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock valued at $646,000 after purchasing an additional 8,540 shares during the last quarter. EntryPoint Capital LLC purchased a new position in Enliven Therapeutics in the 1st quarter valued at $167,000. Finally, Rhumbline Advisers boosted its stake in Enliven Therapeutics by 29.9% during the 2nd quarter. Rhumbline Advisers now owns 49,627 shares of the company’s stock worth $1,160,000 after purchasing an additional 11,420 shares during the last quarter. 95.08% of the stock is owned by hedge funds and other institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.